No Data
No Data
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
Maxim Group Maintains Avenue Therapeutics(ATXI.US) With Buy Rating
Maxim Group analyst Jason McCarthy maintains $Avenue Therapeutics(ATXI.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 29.1% and a total average return of -16.8% o
Express News | Avenue Therapeutics Inc : Maxim Group Cuts Target Price to $12 From $56.25 to Reflect 1-for-75 Reverse Stock Split
Express News | Avenue Therapeutics: Received Notice From Nasdaq Notifying Co Is in Compliance With All Requirement Set Forth in Nasdaq Listing Rule 5550(B)(1)
Express News | Avenue Therapeutics Completes Last Patient Last Visit In Phase 1b/2a Clinical Trial Of AJ201 For Spinal And Bulbar Muscular Atrophy
Express News | Avenue Therapeutics Inc - Topline Data Are Expected to Be Reported Mid-Year 2024
No Data
DuckDucky : Wait for it to go up